Resultados de búsqueda - Cinta Hierro

  • Mostrando 1 - 12 Resultados de 12
Limitar resultados
  1. 1
    HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies

    HER2-Positive Gastric Cancer: The Role of Immunotherapy and Novel Therapeutic Strategies por Anna Pous, L. Notario, Cinta Hierro, Laura Layos, Cristina Bugés

    Publicado 2023
    Enlace del recurso Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  2. 2
    Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?

    Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There? por Cinta Hierro, Ignacio Matos, Juan Martin‐Liberal, María Ochoa de Olza, Elena Garralda

    Publicado 2019
    Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  3. 3
    Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies

    Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies por Marc Cucurull, L. Notario, Montse Sánchez‐Céspedes, Cinta Hierro, Anna Estival, Enric Carcereny, Maria Saigí

    Publicado 2022
    Enlace del recurso Enlace del recurso
    Revisão
    Agregar a favoritos
    Guardado en:
  4. 4
    Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study

    Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in... por Anas Gazzah, Philippe L. Bédard, Cinta Hierro, Yubin Kang, Albiruni Abdul Razak, M.H. Ryu, B. Demers, Nathalie Fagniez, Christophe Henry, Marie Hospitel, J.C. Soria, Josep Tabernero

    Publicado 2022
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  5. 5
    Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring<i>FGF</i>/<i>FGFR</i>Aberrations: A Phase I Dose-Expansion Study

    Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring<i>FGF</i>/<i>FGFR</i>Aberrations: A Phase I Dose-Expansion Study por Funda Meric‐Bernstam, Rastislav Bahleda, Cinta Hierro, Marc Sanson, John Bridgewater, Hendrik‐Tobias Arkenau, Ben Tran, Robin Kate Kelley, Joon Oh Park, Milind Javle, Yaohua He, Karim A. Benhadji, Lipika Goyal

    Publicado 2021
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  6. 6
    Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors

    Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated wi... por Funda Meric‐Bernstam, Hendrik-Tobias Arkenau, Ben Tran, Ratislav Bahleda, Robin Kate Kelley, Cinta Hierro, Daniel H. Ahn, Andrew X. Zhu, Milind Javle, Robert Winkler, Huan He, Jee‐Fu Huang, Lipika Goyal

    Publicado 2018
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  7. 7
    KEYNOTE-590: Phase III Study of First-Line Chemotherapy with or Without Pembrolizumab for Advanced Esophageal Cancer

    KEYNOTE-590: Phase III Study of First-Line Chemotherapy with or Without Pembrolizumab for Advanced Esophageal Cancer por Ken Kato, Manish A. Shah, Peter C. Enzinger, Jaafar Bennouna, Lin Shen, Antoine Adenis, Jong‐Mu Sun, Byoung Chul Cho, Mustafa Özgüroğlu, Takashi Kojima, Vladimir Kostorov, Cinta Hierro, Ying Zhu, Lee Anne McLean, Sukrut Shah, Toshihiko Doi

    Publicado 2019
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  8. 8
    First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas

    First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid... por Sarina A. Piha‐Paul, Ravit Geva, Tira J. Tan, Wan‐Teck Lim, Cinta Hierro, Toshikiko Doi, Osama E. Rahma, Alexander M. Lesokhin, Jason J. Luke, J. Otero, Lisa Nardi, Angad Singh, Alexandros Xyrafas, Xinhui Chen, Jennifer Mataraza, Philippe L. Bédard

    Publicado 2021
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  9. 9
    Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

    Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors por Rastislav Bahleda, Antoîne Italiano, Cinta Hierro, Alain C. Mita, Andrés Cervantes, Nancy Chan, Mark M. Awad, Emiliano Calvo, Víctor Moreno, Ramaswamy Govindan, Alexander I. Spira, Martha Gonzalez, Bob Zhong, Ademi Santiago-Walker, Italo Poggesi, Trilok Parekh, Hong Xie, Jeffrey R. Infante, Josep Tabernero

    Publicado 2019
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  10. 10
    A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterations

    A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring <i>FGFR</i> Gene Alterati... por Martin H. Voss, Cinta Hierro, Rebecca S. Heist, James M. Cleary, Funda Meric‐Bernstam, Josep Tabernero, Filip Janků, Leena Gandhi, A. John Iafrate, Darrell R. Borger, Nobuya Ishii, Youyou Hu, Yulia Kirpicheva, Valerie Nicolas‐Métral, Anna Pokorska-Bocci, Anne Vaslin Chessex, Claudio Zanna, Keith T. Flaherty, José Baselga

    Publicado 2019
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  11. 11
    First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)

    First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK... por Andreas Wicki, Nicholas F. Brown, Alexandros Xyrafas, Vincent Bize, Hanne Hawle, Simona Berardi, Nataša Cmiljanović, Vladimir Cmiljanović, Michael Stumm, Saša Dimitrijević, Richard Herrmann, Vincent Prêtre, Reto Ritschard, Alexandar Tzankov, Viviane Hess, Alexa Childs, Cinta Hierro, Jordi Rodón, Dagmar Hess, Markus Joerger, Roger von Moos, Cristiana Sessa, Rebecca Kristeleit

    Publicado 2018
    Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:
  12. 12
    Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria

    Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria por Ignacio Matos, Juan Martín-Liberal, Alonso García-Ruiz, Cinta Hierro, María Ochoa de Olza, Cristina Viaplana, Analía Azaro, María Vieito, Irene Braña, Gemma Mur, Javier Ros, José M. Mateos, Guillermo Villacampa, Roger Berché, Mafalda Oliveira, María Alsina, Elena Élez, Ana Oaknin, Eva Muñoz‐Couselo, Joan Carles, Enriqueta Felip, Jordi Rodón, Josep Tabernero, Rodrigo Dienstmann, Raquel Pérez-López, Elena Garralda

    Publicado 2019
    Enlace del recurso Enlace del recurso
    Artigo
    Agregar a favoritos
    Guardado en:

Herramientas de búsqueda: